NL-OMON43508已完成4 期
THE TREMOR STUDY: TACROLIMUS EXTENDED RELEASE, MOVEMENT DISORDERS AND OTHER NEUROCOGNITIVE EFFECTS - TREMOR study
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age between 18-70 years
- •Recipient of a kidney transplantation more than one year ago
- •On a triple-low-dose immunosuppressive regimen including tacrolimus
- •Suffering from a tremor
- •Stable renal function
- •Able to give informed consent
排除标准
- •Not being able to understand the instructions for the tests
- •Chronic diarrhea
- •Use of protease inhibitors, azoles or sedatives
- •Thyroid dysfunction
- •Active psychiatric or neurologic disease
- •Use of psychotropic drugs, antiepileptics or B2-agonists
- •Excessive use of caffeine (more than 5 I.E. per day)
- •Excessive use of alcohol (more than 2 I.E. per day)
研究者
相似试验
尚未招募
不适用
ABILITY OF PROLONGED RELEASE TACROLIMUS, TAKEN ONCE DAILY, IN MAINTAINING REMISSION OF CALCINEURIN INHIBITOR DEPENDENT STEROID SENSITIVE NEPHROTIC SYNDROME IN CHILDRECTRI/2022/01/039427All India Institute of Medical Sciences New Delhi
尚未招募
不适用
TARC IN PATIENTS WITH LYMPHADENOPATH, FEVER OR NON-HODGKIN LYMPHOMA-lymphadenopathy-fever-NL-OMON23023niversity Medical Center Groningen300
已完成
不适用
TARC-002 EVALUATION OF THYMUS AND ACTIVATION REGULATED CHEMOKINE (TARC) IN PATIENTS WITH LYMPHADENOPATHY , FEVER OR NON-HODGKIN LYMPHOMAlymphomaNL-OMON45645niversitair Medisch Centrum Groningen300
进行中（未招募）
1 期
A study evaluating the effect of a chemotherapy regimen on the menstrual and ovarian functions of young breast cancer patientsEUCTR2013-000173-77-BEInstitut Jules Bordet50
进行中（未招募）
1 期
A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.InfluenzaCTIS2023-508230-33-00iteVax B.V.70